Flexpet

Flexpet sells joint-health supplements for dogs and cats, offered as chicken-flavored chewable tablets and a newer vegetarian formula. Price sits in the mid-range: a 60-count bottle (≈30-day supply for a 40-lb dog) retails around $40–$45. Distribution is DTC-first through flexpet.com, Amazon and Chewy, with no brick-and-mortar retail presence. The brand’s USP is a patented, plant-based anti-inflammatory compound (CM8®, cetyl myristoleate) combined with glucosamine, MSM, bromelain and vitamin C, all manufactured in a U.S. FDA-inspected facility and backed by a 90-day money-back guarantee. Flexpet positions itself as a natural, side-effect-free alternative to NSAIDs and has built a 15-year testimonial archive of before-and-after mobility stories. Core buyers are 35-65-year-old dog owners whose pets are limping, slowing on stairs, or recovering from surgery; they value holistic care, clean labels and U.S. sourcing and are willing to subscribe for monthly auto-ship discounts. The brand voice is empathetic “pet parent” rather than clinical vet, reinforced by a toll-free helpline staffed by trained “pet mobility specialists.” Flexpet competes in the crowded pet supplement aisle against glucosamine generics and big-pharma pain meds; it differentiates through the proprietary CM8® molecule, a vegetarian option, and a satisfaction guarantee longer than the industry-standard 30 days.